Hayashi I, Onuma K, Hasuike M, Ishii T
Department of Respiratory Disease, Iwaki Kyoritsu General Hospital.
Jpn J Antibiot. 1990 May;43(5):761-7.
Clinical evaluation of ceftibuten (CETB, 7432-S) was performed in 20 patients with acute bronchitis. They were consisted of 10 males and 10 females aged from 20 to 80 years old. CETB was given orally in daily dose of 300 mg (18 cases) or 600 mg (2 cases) in three divided portions. The duration of administration was 3 to 14 days. Especially they were given for 7 days in 16 cases. A total of 11 strains comprising 4 strains of Staphylococcus aureus, 2 strains of beta-Streptococcus and 1 strain each of Streptococcus pneumoniae, Branhamella catarrhalis, Klebsiella oxytoca, Serratia marcescens, Acinetobacter lwoffii were identified from sputa before administration. All of the above bacteria were eradicated but, in 1 case, a strain of Streptococcus pyogenes appeared after the treatment (eradication ratio = 100%). The clinical efficacy rate was 100%: Responses were excellent in 3 cases and good in 17 cases. There was no side effect and no abnormal changes in laboratory test results. From the avobe results, it is concluded that CETB is effective, safe and useful new oral cephem on acute bronchitis.
对20例急性支气管炎患者进行了头孢布烯（CETB，7432 - S）的临床评估。患者包括10名男性和10名女性，年龄在20至80岁之间。CETB口服给药，每日剂量300mg（18例）或600mg（2例），分三次服用。给药持续时间为3至14天，其中16例给药7天。给药前从痰液中鉴定出总共11株菌，包括4株金黄色葡萄球菌、2株β - 链球菌，以及肺炎链球菌、卡他莫拉菌、产酸克雷伯菌、粘质沙雷菌、鲁氏不动杆菌各1株。上述所有细菌均被清除，但治疗后有1例出现化脓性链球菌（清除率 = 100%）。临床有效率为100%：3例反应极佳，17例良好。未出现副作用，实验室检查结果也无异常变化。从上述结果得出结论，CETB是一种治疗急性支气管炎有效、安全且有用的新型口服头孢菌素。
